Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-01-08T21:16:04.893Z Has data issue: false hasContentIssue false
  • English
  • Français

Trazodone in elderly patients with dementia: impact on caregiver burden

Published online by Cambridge University Press:  16 April 2020

E. Pérez ,
J.C. García ,
R. Gandía ,
J.M. Bonete  and
J. Matarredona
E. Pérez
Affiliation:
Hospital Gral. Univ. de Alicante, Alicante, Alcoy, Spain
J.C. García
Affiliation:
Unidad Salud Mental de Aspe, Aspe, Alcoy, Spain
R. Gandía
Affiliation:
Hospital Virgen de los Lirios, Alcoy, Alcoy, Spain
J.M. Bonete
Affiliation:
Unidad Salud Mental de Toscar, Elche, Alcoy, Spain
J. Matarredona
Affiliation:
Unidad Salud Mental de la Fábrica, Alcoy, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Trazodone is a Serotonin-2A Antagonist/Reuptake Inhibitor (SARI) that combines its ability as a 5/HT2A receptor antagonist with some serotonin reuptake blockade actions. Studies support its use in the treatment of behavioral disturbances in patients with Alzheimer's disease and frontotemporal dementia.

Objective

To evaluate the effectiveness of trazodone in behavioral symptoms and caregiver burden in elderly patients with dementia.

Methods

In 49 patients (males and females) older than 65 years with dementia (DSM-IV), trazodone was associated to the standard treatment in a single night variable dose (50–200 mg). On days 0, 14 and 42 neuropsychiatric disorders and caregiver burden (Neuropsychiatric Inventory-Nursing Home Version, NPI-NH) were assessed. On days 0 and 42 cognitive impairment was measured by the test Mini-Mental State Examination (MMSE). The Clinical Global Impression (CGI) was administered on the last visit. Statistical evaluation was done by SPSS 17®.

Results

38 patients completed the study. Global score NPI-NH was significantly reduced (p < 0.001). Sleep quality subscale improved significantly (p < 0.001). The MMSE was not modified. The caregiver burden showed a significant decrease (p < 0.001) on each visit.

Trazodone was well tolerated (main adverse effects were: hypotension (4.1%) and somnolence (2%). Patients evolution was positive (CGI).

Conclusion

Results of this study suggest that trazodone is an effective treatment for behavioral symptoms of dementia. Trazodone reduces caregiver burden without modifying the patient’s cognitive function.

Type
P01-490
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 494
Copyright
Copyright © European Psychiatric Association2011
Submit a response

Comments

No Comments have been published for this article.